JP7063813B2 - 術後認知機能障害の処置のための方法及び医薬組成物 - Google Patents

術後認知機能障害の処置のための方法及び医薬組成物 Download PDF

Info

Publication number
JP7063813B2
JP7063813B2 JP2018542732A JP2018542732A JP7063813B2 JP 7063813 B2 JP7063813 B2 JP 7063813B2 JP 2018542732 A JP2018542732 A JP 2018542732A JP 2018542732 A JP2018542732 A JP 2018542732A JP 7063813 B2 JP7063813 B2 JP 7063813B2
Authority
JP
Japan
Prior art keywords
surgery
aperin
pharmaceutical composition
apj receptor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018542732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508416A (ja
JP2019508416A5 (enExample
Inventor
バレ，フィリップ
ドレイ，セドリック
ミンヴィル，ヴァンサン
フランシス，ベルナール
ラバスト，フランソワ
ヴィネル，クレール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire de Toulouse
Original Assignee
Centre Hospitalier Universitaire de Toulouse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire de Toulouse filed Critical Centre Hospitalier Universitaire de Toulouse
Publication of JP2019508416A publication Critical patent/JP2019508416A/ja
Publication of JP2019508416A5 publication Critical patent/JP2019508416A5/ja
Application granted granted Critical
Publication of JP7063813B2 publication Critical patent/JP7063813B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018542732A 2016-02-15 2017-02-14 術後認知機能障害の処置のための方法及び医薬組成物 Active JP7063813B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305170 2016-02-15
EP16305170.9 2016-02-15
PCT/EP2017/053308 WO2017140684A2 (en) 2016-02-15 2017-02-14 Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction

Publications (3)

Publication Number Publication Date
JP2019508416A JP2019508416A (ja) 2019-03-28
JP2019508416A5 JP2019508416A5 (enExample) 2020-01-23
JP7063813B2 true JP7063813B2 (ja) 2022-05-09

Family

ID=55359484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018542732A Active JP7063813B2 (ja) 2016-02-15 2017-02-14 術後認知機能障害の処置のための方法及び医薬組成物

Country Status (5)

Country Link
US (3) US11484577B2 (enExample)
EP (1) EP3416688B1 (enExample)
JP (1) JP7063813B2 (enExample)
ES (1) ES2930077T3 (enExample)
WO (1) WO2017140684A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3931178B1 (en) * 2019-03-01 2025-06-25 Abrexa Pharmaceuticals, Inc. Compounds for prevention and treatment of post-operative cognitive dysfunction
CA3177262A1 (en) * 2020-04-28 2021-11-04 Jesus E. Villafranca Compounds for prevention and treatment of post-intensive care cognitive dysfunction and cognitive dysfunction resulting from respiratory distress
WO2023211684A2 (en) * 2022-04-29 2023-11-02 Noetix Pharma Llc Prevention and treatment of post-operative cognitive dysfunction (pocd)

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932667A (en) 1971-08-02 1976-01-13 Airco, Inc. Ether compound as an inhalation anesthetic
US3954893A (en) 1971-08-09 1976-05-04 W. R. Grace & Co. New halogenated cyclobutanes
US3987203A (en) 1973-03-16 1976-10-19 Airco, Inc. Anesthetizing composition and method
DE2340560C2 (de) 1973-08-10 1982-12-16 Hoechst Ag, 6000 Frankfurt 1.2.2.2-Tetrafluoräthyl-äther, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltendes Inhalations-Anästhetikum
DE2340561C2 (de) 1973-08-10 1982-12-16 Hoechst Ag, 6000 Frankfurt 2.2.2-Trifluor-1-chloräthyl-äther und Verfahren zu ihrer Herstellung sowie Inhalations-Anästhetikum, das einen dieser Stoffe enthält
US3987100A (en) 1974-04-11 1976-10-19 E. I. Du Pont De Nemours And Company Cyclohexane oxidation in the presence of binary catalysts
US3949005A (en) 1974-05-09 1976-04-06 Airco, Inc. Hexafluoro-t-butyl-difluoromethyl ether as an inhalation anesthetic
US3931344A (en) 1974-08-22 1976-01-06 W. R. Grace & Co. Bromofluorocyclopropanes
US3932529A (en) 1974-12-26 1976-01-13 W. R. Grace & Co. Halocyclopropyl halomethyl ethers
US3995062A (en) 1974-12-26 1976-11-30 W. R. Grace & Co. Halocyclopropyl halomethyl ethers
US3932669A (en) 1975-01-10 1976-01-13 W. R. Grace & Co. 1-Chloro-2,2-dimethyl-1,4,4-trifluorocyclobutane as an anesthetics
US4220644A (en) 1976-05-03 1980-09-02 Smithkline Corporation 7-Acylamino-3-(substituted tetrazolyl thiomethyl) cephalosporins
US4281020A (en) 1979-03-01 1981-07-28 The Dow Chemical Company Deuterated analogues of methoxyflurane useful as an anesthetic
US4346246A (en) 1979-03-12 1982-08-24 Airco, Inc. Process for adjusting the halogen content of halogenated aliphatic ethers
US4262144A (en) 1979-10-25 1981-04-14 The Dow Chemical Company Deuterated isoflurane
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5391579A (en) 1993-01-28 1995-02-21 University Of Iowa Research Foundation Deuterated sevoflurane as an inhalational anesthetic
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
EP1040189B1 (en) 1997-12-24 2008-01-09 Takeda Pharmaceutical Company Limited Polypeptides, their production and use
AU2001242749A1 (en) 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Peptide derivative
US7947280B2 (en) 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
US20050112701A1 (en) 2003-09-11 2005-05-26 Aventis Pharma Deutschland Gmbh Test system for the identification of APJ receptor ligands
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US9308232B2 (en) * 2006-06-05 2016-04-12 Keyview Labs, Inc. Compositions and methods for enhancing brain function
EP1903052A3 (en) 2006-07-28 2008-04-02 Faust Pharmaceuticals SA APJ receptor ligands and uses thereof
US20100113570A1 (en) * 2008-04-23 2010-05-06 The General Hospital Corporation Prevention and treatment of post-operative cognitive dysfunction
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
US20120316247A1 (en) * 2009-10-20 2012-12-13 The General Hospital Corporation Prevention and treatment of post-operative cognitive dysfunction (pocd)
EP2547363B1 (en) * 2010-02-17 2020-06-03 The Kennedy Trust For Rheumatology Research Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist
DK2643782T3 (da) * 2010-11-24 2020-11-09 Digital Artefacts Llc Systemer og fremgangsmåder til bedømmelse af kognitiv funktion
UY35144A (es) * 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
AU2014284496A1 (en) * 2013-07-03 2016-01-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for treating cognitive dysfunction
GB201311948D0 (en) 2013-07-03 2013-08-14 British American Tobacco Co Curling Machine
SG11201600211XA (en) 2013-07-25 2016-02-26 Novartis Ag Cyclic polypeptides for the treatment of heart failure
TW201518323A (zh) 2013-07-25 2015-05-16 Novartis Ag 合成ａｐｅｌｉｎ多肽之生物結合物
WO2015013165A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Peptides, (2013), 39, p.171-174

Also Published As

Publication number Publication date
JP2019508416A (ja) 2019-03-28
WO2017140684A3 (en) 2017-12-21
US20210196798A1 (en) 2021-07-01
ES2930077T3 (es) 2022-12-07
US20240226238A1 (en) 2024-07-11
US11484577B2 (en) 2022-11-01
EP3416688B1 (en) 2022-08-17
EP3416688A2 (en) 2018-12-26
US11896649B2 (en) 2024-02-13
US20230093887A1 (en) 2023-03-30
WO2017140684A2 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
US20240226238A1 (en) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
PT2371865T (pt) ANTICORPOS QUE SE LIGAM À FOSFATASE TIROSINA DE PROTEÍNAS HUMANA BETA (FTPH-ß) E SUAS UTILIZAÇÕES
JP6319847B2 (ja) 軸索再生を促進するための脊髄装置および方法
CN117618534A (zh) Hmgb1蛋白的片段肽的制药用途
US20170252438A1 (en) Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
KR20150109386A (ko) 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체
JP2024537864A (ja) 新規併用投与
WO2014130949A1 (en) Methods and compositions for the treatment of bone remodeling disorders
US20240293514A1 (en) Pharmaceutical compositions comprising glp-1r agonists
CN109966488A (zh) 周围神经的IgG刺激髓鞘再生
JP2015514771A (ja) 神経保護性組成物および使用方法
CN113288904B (zh) Mitoquinone在制备预防和/或治疗运动损伤的药物中的应用
RU2413548C1 (ru) Способ лечения остеоартроза коленного сустава
US20120225821A1 (en) Composition for preventing or treating a spinal cord injury
TWI611805B (zh) 用於治療坐骨神經損傷之醫藥組合物
TW200934790A (en) Methods for inhibition of scarring
CN120858111A (zh) 用于治疗子宫内膜异位症和相关疼痛的抗轴突导向因子-1单克隆抗体
JP2025511167A (ja) 顔面肩甲上腕型筋ジストロフィー（ｆｓｈｄ）の新規な処置
JP6875988B2 (ja) 損傷末梢神経治療用組成物
RU2446834C2 (ru) Способ лечения пострадавших с сочетанной черепно-мозговой травмой
Casson Three Cases of Anthrax Treated Successfully by the Hypodermic Injection of Mercuric Perchloride
JPWO2014088106A1 (ja) 線維筋痛症の予防または治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220421

R150 Certificate of patent or registration of utility model

Ref document number: 7063813

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250